Rethinking Clinical Trials
DECEMBER 20, 2023
Yet enrollment of ethnic minorities in NIH clinical trials and for trials studying approved devices and drugs remains low. Increasing diversity in trial leadership is one of the most important strategies to increase diversity among RCT participants. The biggest barrier for CV medicine is the lack of women leaders in CV.
Velocity Clinical Research
NOVEMBER 21, 2023
“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
JULY 12, 2023
Neha Pagidipati In this Friday’s PCT Grand Rounds, Christopher Granger and Neha Pagidipati of Duke University will present “Lessons From the COORDINATE-Diabetes Trial.” Fortin, MD, Distinguished Professor of Medicine and a professor of nursing, and Dr. Pagidipati is an associate professor of medicine—both at Duke University.
WCG Clinical
MAY 22, 2023
Despite the growing consensus around the need for diversity in clinical trials, the industry still has a long way to go. 4,5 In fact, lack of representation in clinical trials compromises generalizability of research findings. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers.
Pharmaceutical Technology
JUNE 21, 2023
It can be used as a monotherapy or along with cholesterol-lowering medicines. The regulatory approval was based on the findings obtained from a double-blind, multinational, placebo-controlled, randomised clinical trial conducted in 5,522 chronic coronary disease patients.
Rethinking Clinical Trials
JUNE 7, 2023
Tags #pctGR, @Collaboratory1 The post Grand Rounds June 2, 2023: PROACT Xa and The Wizard of Oz: Behind the Curtain of a Pragmatic Decentralized Clinical Trial (John Alexander, MD, MHS) appeared first on Rethinking Clinical Trials.
XTalks
NOVEMBER 19, 2021
Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.
Expert insights. Personalized for you.
173 
Let's personalize your content